Terns Pharmaceuticals Inc., trading on NASDAQ under the symbol TERN, has released a corporate presentation highlighting its progress as of June 2025. The company is advancing two differentiated clinical assets, TERN-701 and TERN-601, with significant milestones anticipated in the fourth quarter of 2025. TERN-701, an allosteric BCR-ABL inhibitor, aims to address chronic myeloid leukemia $(CML.UK)$ in a market exceeding $5 billion. Meanwhile, TERN-601, an oral GLP-1 receptor agonist, targets obesity with potential competitive weight loss and superior tolerability. Both programs are progressing through clinical trials, with TERN-701 in Phase 1 and TERN-601 in Phase 2. Terns Pharmaceuticals has secured a cash runway of $334 million to support its development pipeline into 2028. You can access the full presentation through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。